Announcement PDF ASX/Media Release 11/05/2020 Emerald Clinics appointed program manager of National Clinical Data and Analytics Platform (CDAP) targeted at COVID-19 response Highlights - - Emerald engaged to play key role in the development of a National Clinical Data and Analytics Platform (CDAP) for COVID-19 cases to enable learning from the treatment of patients CDAP is expected to be launched on 11 May 2020 as a partnership between NSW Health, Queensland Health, the Queensland University of Technology (QUT), the University of Sydney, and Monash University CDAP is focused on clinical and real-world data capture and real-time clinical decision support, supporting new clinical trials and the long-term follow up of patients Emerald Clinics Limited (ASX: EMD) (Emerald or the Company), a Real-World Evidence (RWE) data platform company supporting accelerated development of therapeutics, is pleased to announce it has been appointed as Program Manager for the development of a National clinical data and analytics platform of COVID-19 patient cases in a partnership between several Australian State health bodies, the Federal Government and universities. The Clinical Data and Analytics Platform (CDAP) aims to collect clinical data from confirmed COVID-19 patients, from a variety of sources, in close to real-time. The data will be analysed to inform predictive models that can support point-of-care decision making by clinicians across likely disease progression as well as treatment options for each patient. In addition, the platform is expected to underpin a series of planned adaptive trials of COVID-19 treatment protocols while allowing for forecasting of likely demand on health services. The project has been established by the Digital Health Cooperative Research Centre and is a partnership between NSW Health, Queensland Health, QUT, the University of Sydney, and Monash University. Emerald Clinics was selected by the University of Sydney to lead the program management across the entire project including coordinating the data integration efforts across multiple health services and the analytical model design. “We are very pleased to be chosen to help co-ordinate the development of this platform, as it is a recognition of Emerald’s unique expertise in real-world evidence and building learning health systems.” said Emerald Clinics Managing Director, Dr Michael Winlo. University of Sydney epidemiologist and infectious diseases expert, Professor Tom Snelling, said “Medical professionals are currently working with incomplete and inaccurate information, and we expect CDAP to provide a clear, national data picture on the stages of COVID-19, the impact of the disease on the individual, as well as their care and recovery needs.” “We are pleased to work with Emerald to develop CDAP given their commitment to real-world evidence and building learning health systems,” he said. Emerald’s business is focused on developing valuable high-quality real-world evidence (RWE) data around the safe and effective use of medicines, to improve patient care, to identify novel uses of existing or new therapeutics and to explore the post-approval performance of certain medicines, all leveraging Emerald’s proprietary data platform. RWE is observational data (drawn from health records, patient vital sign tracking technologies, medicine usage patterns, side effect reporting and other useful data), that is obtained outside the context of the pharmaceutical industry’s usual “randomized controlled trials” and is mostly generated during routine interaction with a patient in a real world setting. Emerald’s data platform is specifically designed to capture, analyse and provide new insights into these realworld issues and provide this valuable data on a subscription payment, or data acquisition model, to pharmaceutical companies, regulators and other health industry stakeholders. This initial work order will deliver revenue to Emerald of $100,000 within 12 months and is the first work order under a master services agreement. The Emerald platform will be managed in close association with frontline clinicians across participating institutions. It will also utilise existing state and territory resources and digital capabilities. The CDAP project is focused on the following goals: - Data capture – to quickly and efficiently capture diagnostic and treatment data of COVID-19 patients across the Australian healthcare system - Real-time clinical decision support – to assist clinicians treating or supporting COVID-19 patients - Supporting new clinical trials – to quickly implement clinical trials with the best information and analytics to improve treatment allocations to trial patients; and - Long-term follow-up of patients – to allow for continued monitoring and treatment of those diagnosed with, or recovering from, COVID-19 in the longer term Emerald’s data platform continues to expand with multiple clinical trial and collaboration opportunities already secured in addition to this CDAP opportunity. The Company expects to further leverage its unique data gathering experience across multiple verticals in the coming months as the health system pivots strongly to remote and contactless clinical trials and service delivery. Release authorised by: Dr Michael Winlo, CEO and Managing Director For further information: Dr Michael Winlo CEO (08) 6559 2800 investors@emeraldclinics.com.au Matt Wright Media/investor relations +61 (0) 451 896 420 matt@nwrcommunications.com.au About Emerald Clinics Limited Emerald Clinics Limited (ACN 625 085 734) is an Australian incorporated company that operates a network of specialist medical clinics (Clinics) and uses purpose-built software and technology to gather high quality clinical data from informed and consenting patients to create robust and ethically sourced evidence. Emerald is a clinical services and healthcare technology company focussed on the provision of care for patients clinically determined to have exhausted conventional therapies and who may be suitable for cannabinoid-based medicines. In addition, Emerald uses technology to capture clinical data that can be used to generate clinical evidence relating to the safety and efficacy of unregistered medicines. Emerald has established four medical centres in Australia in Perth, Sydney, Melbourne and Northern Rivers NSW. Cautionary Note on Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a results of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forwardlooking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.